Dr Porshia Gabrielle Underwood, MD | |
325 9th Ave, Seattle, WA 98104-2420 | |
(206) 520-5000 | |
Not Available |
Full Name | Dr Porshia Gabrielle Underwood |
---|---|
Gender | Female |
Speciality | Obstetrics/gynecology |
Experience | 8 Years |
Location | 325 9th Ave, Seattle, Washington |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205299609 | NPI | - | NPPES |
1205299609 | Medicaid | WA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | MD61048422 (Washington) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Harborview Medical Center | Seattle, WA | Hospital |
University Of Washington Medical Ctr | Seattle, WA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
The Association Of University Physicians | 0446162697 | 3009 |
News Archive
Academic and government leaders announced today the establishment of a major new research institute at The University of Texas MD Anderson Cancer Center that will blend the best attributes of academic and industrial research to identify and validate new cancer targets, convert such scientific knowledge into new cancer drugs, and advance these novel agents into innovative clinical trials.
A local businesswoman has been nominated for the Outstanding Contribution to Breast Cancer Campaign 2010 Award after raising more than £15,000 for the charity through her passion for dolls houses and miniatures.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
University of Cincinnati pharmaceutical sciences researcher Bingfang Yan, DVM, has received a $443,000 grant from the National Institutes of Health to study how common medicines against viral infections are genetically impacted for therapeutic effectiveness and safety through metabolic conversions in the body.
An estimated 2.3 million people living with HIV are co-infected with hepatitis C virus (HCV) globally, a new study by the University of Bristol and the London School of Hygiene & Tropical Medicine has found.
› Verified 1 days ago
Entity Name | The Association Of University Physicians |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
Academic and government leaders announced today the establishment of a major new research institute at The University of Texas MD Anderson Cancer Center that will blend the best attributes of academic and industrial research to identify and validate new cancer targets, convert such scientific knowledge into new cancer drugs, and advance these novel agents into innovative clinical trials.
A local businesswoman has been nominated for the Outstanding Contribution to Breast Cancer Campaign 2010 Award after raising more than £15,000 for the charity through her passion for dolls houses and miniatures.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
University of Cincinnati pharmaceutical sciences researcher Bingfang Yan, DVM, has received a $443,000 grant from the National Institutes of Health to study how common medicines against viral infections are genetically impacted for therapeutic effectiveness and safety through metabolic conversions in the body.
An estimated 2.3 million people living with HIV are co-infected with hepatitis C virus (HCV) globally, a new study by the University of Bristol and the London School of Hygiene & Tropical Medicine has found.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Porshia Gabrielle Underwood, MD Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 520-5700 | Dr Porshia Gabrielle Underwood, MD 325 9th Ave, Seattle, WA 98104-2420 Ph: (206) 520-5000 |
News Archive
Academic and government leaders announced today the establishment of a major new research institute at The University of Texas MD Anderson Cancer Center that will blend the best attributes of academic and industrial research to identify and validate new cancer targets, convert such scientific knowledge into new cancer drugs, and advance these novel agents into innovative clinical trials.
A local businesswoman has been nominated for the Outstanding Contribution to Breast Cancer Campaign 2010 Award after raising more than £15,000 for the charity through her passion for dolls houses and miniatures.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
University of Cincinnati pharmaceutical sciences researcher Bingfang Yan, DVM, has received a $443,000 grant from the National Institutes of Health to study how common medicines against viral infections are genetically impacted for therapeutic effectiveness and safety through metabolic conversions in the body.
An estimated 2.3 million people living with HIV are co-infected with hepatitis C virus (HCV) globally, a new study by the University of Bristol and the London School of Hygiene & Tropical Medicine has found.
› Verified 1 days ago
Dr. Jaime Marie Michaelson, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 310 15th Ave E, Seattle, WA 98112 Phone: 206-326-3000 | |
Alisa Beth Kachikis, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1959 Ne Pacific St, 3rd Floor Sw 350, Seattle, WA 98195 Phone: 206-598-4070 | |
Karen L. Bohmke, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1101 Madison St, #1150, Seattle, WA 98104 Phone: 206-386-3400 | |
Lisa S. Callegari, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-520-5000 | |
Anne-marie Elizabeth Amies Oelschlager, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Uwmc-roosevelt, 4245 Roosevelt Way Ne, Seattle, WA 98105 Phone: 206-598-5500 | |
Shirley Andrews, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1560 N 115th St Ste 212, Seattle, WA 98133 Phone: 206-363-2800 Fax: 206-363-2811 | |
Lyndsey Summer Benson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Box 356460, Seattle, WA 98195 Phone: 610-202-4028 |